Jana Partners’s Sage Therapeutics SAGE Stock Holding History

Jana Partners’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-198,406	Closed	-$10.1M	–	62
2016 Q4	$10.1M	Buy	198,406 +87,279	+79%	+$4.11M	0.18%	36
2016 Q3	$5.12M	Buy	+111,127	New	+$4.52M	0.09%	38

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Jana Partners's SAGE Position: Q1 2017 in Review

Jana Partners sold out of Sage Therapeutics (SAGE) in Q1 2017, closing a stake of 198,406 shares — an estimated $10.1M sold.

Jana Partners first reported a position in SAGE in Q3 2016 and held it in 2 quarters. The position peaked at $10.1M in Q4 2016. 190 funds tracked by Wall St. Rank hold SAGE as of Q1 2017.

Jana Partners reported no remaining Sage Therapeutics position as of Q1 2017 after selling out during the quarter.
Jana Partners sold 198,406 Sage Therapeutics shares in Q1 2017, an estimated $10.1M.
Jana Partners first reported a position in Sage Therapeutics in Q3 2016 and held it in 2 quarters.
Jana Partners's Sage Therapeutics position peaked at $10.1M in Q4 2016.
190 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2017.

Based on Jana Partners's 13F filing for Q1 2017, filed 15 May 2017.